Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Karin Enell Smith"'
Autor:
Hampus Andersson, Aastha Sobti, David Gomez Jimenez, Yago Pico de Coaña, Sumeet Vijay Ambarkhane, Karin Hägerbrand, Karin Enell Smith, Malin Lindstedt, Peter Ellmark
Publikováno v:
Cells, Vol 12, Iss 19, p 2365 (2023)
CD40-targeting therapies can enhance the dendritic cell priming of tumor-specific T cells and repolarize intratumoral macrophages to alleviate the tumoral immunosuppressive environment and remodel the extracellular matrix. Mitazalimab is a potent ago
Externí odkaz:
https://doaj.org/article/a7afa486b011446eac4b1806acb30e5d
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/38604b7479d14b0fb4c53e62dc3cf3da
Autor:
Anne Månsson Kvarnhammar, Niina Veitonmäki, Karin Hägerbrand, Anna Dahlman, Karin Enell Smith, Sara Fritzell, Laura von Schantz, Mia Thagesson, Doreen Werchau, Kristine Smedenfors, Maria Johansson, Anna Rosén, Ida Åberg, Magnus Winnerstam, Eva Nyblom, Karin Barchan, Christina Furebring, Per Norlén, Peter Ellmark
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-14 (2019)
Abstract Background The CTLA-4 blocking antibody ipilimumab has demonstrated substantial and durable effects in patients with melanoma. While CTLA-4 therapy, both as monotherapy and in combination with PD-1 targeting therapies, has great potential in
Externí odkaz:
https://doaj.org/article/ac146a36143540ed83d59ae4ac9773f4
Autor:
Malin Lindstedt, Peter Ellmark, Aastha Sobti, Karin Enell Smith, Yago Pico de Coaña, Sumeet Ambarkhane
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Peter Ellmark, Adnan Deronic, Mia Thagesson, Karin Enell Smith, Doreen Werchau, Anneli Nilsson
Publikováno v:
Cancer Immunology, Immunotherapy
Non-responders to checkpoint inhibitors generally have low tumor T cell infiltration and could benefit from immunotherapy that activates dendritic cells, with priming of tumor-reactive T cells as a result. Such therapies may be augmented by providing
Autor:
Jean-Luc Van Laethem, Ivan Borbath, Hans Prenen, Aurélien Lambert, Karen Geboes, Jean-Frédéric Blanc, Yago Pico de Coaña, Karin Enell-Smith, Lena Schultz, Karin Nordbladh, Peter Ellmark, Sumeet Ambarkhane, Malin Carlsson, Philippe Cassier
Publikováno v:
Cancer Research. 82:A018-A018
Mitazalimab is a human CD40 agonistic IgG1antibody being developed as cancer immunotherapy. Targeting CD40 kickstarts the cancer immunity cycle by licensing DCs leading to tumor-specific T cell priming and activation. Furthermore, in PDAC, CD40 agoni
Publikováno v:
Expert opinion on biological therapy. 21(12)
Introduction: CD40 signaling activates dendritic cells leading to improved T cell priming against tumor antigens. CD40 agonism expands the tumor-specific T cell repertoire and has the potential to increase the fraction of patients that respond to est
Publikováno v:
Cancer Research. 82:4155-4155
Mitazalimab is a human CD40 agonistic antibody developed for immunotherapy of cancer. Activation of CD40, expressed on myeloid cells, such as dendritic cells and tumor infiltrating macrophages, leads to improved T cell priming and initiation of T cel
Autor:
Gustav J. Ullenhag, Ana Carneiro, Karin Enell Smith, Lena Schultz, Sumeet Vijay Ambarkhane, Tova Landstrom, Jeffrey Yachnin
Publikováno v:
Journal of Clinical Oncology. 40:2529-2529
2529 Background: ATOR-1017 is a human agonist Fcγ-receptor cross-linking dependent IgG4 antibody targeting the co-stimulatory receptor 4-1BB (CD137). ATOR-1017 activates T cells and natural killer cells in the tumor environment, leading to immune-me
Autor:
Jean-Luc Van Laethem, Ivan Borbath, Hans Prenen, Yago Pico de Coaña, Karin Enell Smith, Karin Nordbladh, Peter Ellmark, Sumeet Vijay Ambarkhane, Malin Carlsson, Philippe Alexandre Cassier
Publikováno v:
Journal of Clinical Oncology. 40:e16237-e16237
e16237 Background: Mitazalimab is a human CD40 agonistic IgG1antibody being developed for cancer immunotherapy. Targeting CD40 kickstarts the cancer immunity cycle by licensing DCs leading to tumor-specific T cell priming and activation. Furthermore,